Insider Trading disclosures for Terns Pharmaceuticals Inc

The latest disclosure was made by Andrew Gengos in Terns Pharmaceuticals Inc where a trade of 750,000 Stock Option (Right to Buy) done was reported to US exchanges on Feb. 24, 2025.

Insider trading is the trading of a company’s securities by individuals with access to confidential or material non-public information about the company. A company is required to report trading by corporate officers, directors, or other company members with significant access to privileged information to the Securities and Exchange Commission (SEC).

Show

Client Name	Client Category	Action	Reported to Exchange	Quantity	Post Transaction Holding	Traded %	Avg. Price	Value	Security Type
Andrew Gengos	Chief Financial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	24 Feb 2025	750,000	750,000	-		-	Stock Option (Right to Buy)
Robert W. Azelby	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	20 Feb 2025	90,000	90,000	-		-	Stock Option (Right to Buy)
Jeffrey B. Kindler	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	01 Feb 2025	10,657	10,657	-		-	Stock Option (Right to Buy)
David Fellows	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	01 Feb 2025	18,650	18,650	-		-	Stock Option (Right to Buy)
Radhika Tripuraneni	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	01 Feb 2025	10,657	10,657	-		-	Stock Option (Right to Buy)
Hongbo Lu	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	01 Feb 2025	10,657	10,657	-		-	Stock Option (Right to Buy)
Jill M. Quigley	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	01 Feb 2025	10,657	10,657	-		-	Stock Option (Right to Buy)
Amy Burroughs	Director, Chief Executive Officer	Purchase of securities on an exchange or from another person at price $ 5.11 per share.	30 Jan 2025	510	19,609	-	5.1	2,606	Common Stock
Amy Burroughs	Director, Chief Executive Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	30 Jan 2025	1,075,000	1,075,000	-		-	Stock Option (Right to Buy)
Emil T. Kuriakose	Chief Medical Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	30 Jan 2025	485,000	485,000	-		-	Stock Option (Right to Buy)
Melita Sun Jung	Chief Business Officer	Purchase of securities on an exchange or from another person at price $ 5.11 per share.	30 Jan 2025	2,250	2,250	-	5.1	11,498	Common Stock
Melita Sun Jung	Chief Business Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	30 Jan 2025	325,000	325,000	-		-	Stock Option (Right to Buy)
Mark J. Vignola	Chief Financial Officer		02 Jan 2025	8,129	83,811	-	5.7	46,524	Common Stock
Mark J. Vignola	Chief Financial Officer		02 Jan 2025	9,059	74,752	-	5.8	52,500	Common Stock
Jill M. Quigley	Director	Sale of securities on an exchange or to another person at price $ 5.72 per share.	02 Jan 2025	6,240	8,760	-	5.7	35,702	Common Stock
Jill M. Quigley	Director	Sale of securities on an exchange or to another person at price $ 5.79 per share.	02 Jan 2025	8,760	0	-	5.8	50,758	Common Stock
Emil T. Kuriakose	Chief Medical Officer	Sale of securities on an exchange or to another person at price $ 5.71 per share.	02 Jan 2025	4,481	54,269	-	5.7	25,607	Common Stock
Emil T. Kuriakose	Chief Medical Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Dec 2024	120,000	120,000	-		-	Stock Option (Right to Buy)
Amy Burroughs	Director, Chief Executive Officer	Purchase of securities on an exchange or from another person at price $ 7.15 per share.	05 Dec 2024	15,450	19,099	-	7.2	110,468	Common Stock
Heather D. Turner	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	18 Nov 2024	64,000	64,000	-		-	Stock Option (Right to Buy)
Hongbo Lu	Director	Purchase of securities on an exchange or from another person at price $ 10.50 per share.	12 Sep 2024	285,714	476,190	-	10.5	2,999,997	Common Stock
Hongbo Lu	Director	Purchase of securities on an exchange or from another person at price $ 10.50 per share.	12 Sep 2024	190,476	190,476	-	10.5	1,999,998	Common Stock
Mark J. Vignola	Chief Financial Officer		10 Sep 2024	10,000	55,000	-		-	Stock Option (Right to Buy)
Mark J. Vignola	Chief Financial Officer		10 Sep 2024	10,000	91,940	-	11	110,000	Common Stock
Mark J. Vignola	Chief Financial Officer		10 Sep 2024	10,000	101,940	-	5.4	53,600	Common Stock
Jill M. Quigley	Director	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	09 Sep 2024	17,235	0	-		-	Stock Option (Right to Buy)
Jill M. Quigley	Director	Sale of securities on an exchange or to another person at price $ 10.00 per share.	09 Sep 2024	17,235	15,000	-	10	172,350	Common Stock
Jill M. Quigley	Director	Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.82 per share.	09 Sep 2024	17,235	32,235	-	1.8	31,368	Common Stock
Jill M. Quigley	Director	Sale of securities on an exchange or to another person at price $ 7.68 per share.	01 Aug 2024	6,143	23,857	-	7.7	47,148	Common Stock
Jill M. Quigley	Director	Sale of securities on an exchange or to another person at price $ 7.50 per share.	01 Aug 2024	8,857	15,000	-	7.5	66,432	Common Stock
Carl L. Gordon	Director, Ten Percent Owner		15 Jul 2024	39,433	4,843,421	-	10	394,330	Common Stock
Carl L. Gordon	Director, Ten Percent Owner		15 Jul 2024	623	755,635	-	10	6,230	Common Stock
Carl L. Gordon	Director, Ten Percent Owner		15 Jul 2024	556	1,967,924	-	10	5,560	Common Stock
Carl L. Gordon	Director, Ten Percent Owner		15 Jul 2024	4,009	4,839,412	-	10	40,090	Common Stock
Carl L. Gordon	Director, Ten Percent Owner		15 Jul 2024	6,142	756,258	-	10	61,420	Common Stock
Carl L. Gordon	Director, Ten Percent Owner		15 Jul 2024	5,401	1,968,480	-	10	54,010	Common Stock
Jill M. Quigley	Director	Sale of securities on an exchange or to another person at price $ 10.00 per share.	15 Jul 2024	14,365	30,000	-	10.0	143,660	Common Stock
Jill M. Quigley	Director	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	15 Jul 2024	400	17,235	-		-	Stock Option (Right to Buy)
Jill M. Quigley	Director	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	15 Jul 2024	14,365	17,635	-		-	Stock Option (Right to Buy)
Jill M. Quigley	Director	Sale of securities on an exchange or to another person at price $ 10.00 per share.	15 Jul 2024	400	30,000	-	10	4,000	Common Stock
Jill M. Quigley	Director	Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.82 per share.	15 Jul 2024	400	30,400	-	1.8	728	Common Stock
Jill M. Quigley	Director	Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.82 per share.	15 Jul 2024	14,365	44,365	-	1.8	26,144	Common Stock
Carl L. Gordon	Director, Ten Percent Owner		01 Jul 2024	4,676	4,676	-		-	Stock Option (Right to Buy)
Jeffrey B. Kindler	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	01 Jul 2024	4,676	4,676	-		-	Stock Option (Right to Buy)
David Fellows	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	01 Jul 2024	8,183	8,183	-		-	Stock Option (Right to Buy)
Radhika Tripuraneni	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	01 Jul 2024	4,676	4,676	-		-	Stock Option (Right to Buy)
Hongbo Lu	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	01 Jul 2024	4,676	4,676	-		-	Stock Option (Right to Buy)
Ann E. Taylor	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	01 Jul 2024	4,676	4,676	-		-	Stock Option (Right to Buy)
Carl L. Gordon	Director, Ten Percent Owner		10 Jun 2024	32,000	32,000	-		-	Stock Option (Right to Buy)
Jeffrey B. Kindler	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	10 Jun 2024	32,000	32,000	-		-	Stock Option (Right to Buy)

Showing 1 to 50 of 118 entries

*All Values are in $ Million

Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures

Data as reported to USA Exchanges

View All The Insider Trades disclosures

New 52W Low in past week

Insider Trading disclosures for Terns Pharmaceuticals Inc

The latest disclosure was made by Andrew Gengos in Terns Pharmaceuticals Inc where a trade of 750,000 Stock Option (Right to Buy) done was reported to US exchanges on Feb. 24, 2025.

Screeners based on Insider Trading and SAST parameters